welcome

 

AROMICS is a biotech company committed to the discovery and development of novel drugs and diagnostic methods to target relevant human diseases and improve patient’s quality of life.

We believe that OMIC technologies represent an important first step towards gaining biological insights into:

  • How drugs work, giving them added value, reducing attrition rates and advancing  through the clinic.
  • Determining clinically predictive molecular endpoints that help physicians manage the disease, drive prescriptions and monitor drug response.

latest news and events

 

May 2016

SEAP-IAP: LIQUID BIOPSY: NEW CHALLENGES FOR PATHOLOGIST AND ONCOLOGIST

Dr. Carmen Plasencia, CEO of AROMICS, will assist to the meeting organized by the Spanish Society...

mas noticias

 

March 2016

AROMICS at the 16th ESADEBAN Forum

Aromics one of the participants of the 16th healthcare Investment Forum, coorganized by ESADEBAN,...

mas noticias

 

With 35,000 genes and hundreds of thousands of protein states to identify, correlate, and characterize, the studies of one gene, gene product, or process are no longer reliable or cost-effective. We have entered the "omic" era in biology. But large- scale omic studies of cellular molecules in aggregate rarely answer interesting questions without the assistance of information from traditional hypothesis- driven research. These scientific methods are complementary and synergistic.

John N. Weinstein. Disease Markers 17(2): 77- 88, 2001.